Doxorubicin Induced Cardiomyopathy (DBCOND0078390)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Dexrazoxane	A cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer.	DNA topoisomerase 2-alphatarget DNA topoisomerase 2-betatarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02796365	Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy	No drug interventions	prevention	Not Available	completed
NCT02677714	99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer	No drug interventions	diagnostic	2	terminated
NCT04461223	Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR	No drug interventions	Not Available	Not Available	unknown_status
NCT05792293	Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity	Atorvastatin	prevention	2 / 3	recruiting
NCT05731375	Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT06092606	A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients	No drug interventions	prevention	2	recruiting
NCT03000036	Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients	Doxorubicin Gadoteric acid	diagnostic	Not Available	completed
NCT06427226	Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	Dapagliflozin	prevention	2	not_yet_recruiting